ELVR in PH Patients With Severe Emphysema

Effect of Endoscopic Lung Volume Reduction (ELVR) on Pulmonary Hypertension (PH) in Patients With Severe Emphysema and Pulmonary Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01393379

Enrollment

Registered

2011-07-13

Start date

2010-04-30

Completion date

2014-12-31

Last updated

2015-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Pulmonary Emphysema

Brief summary

The purpose of this study is to investigate the effect of endoscopic valve implantation in patients with COPD and PH on hemodynamics, symptoms, exercise tolerance and quality of life in 10 patients in a prospective study. An improvement of objective parameters may also have a prognostic significance

Detailed description

So far there is no treatment of COPD in addition to the established treatment of concomitant PH. Administration of PH-specific medication outside of clinical trials is not recommended in new guidelines for PH of the ERS/ESC. The influence of endobronchial valve implantation on the PH has not been studied in detail. The purpose of this study is to investigate the effect of endoscopic valve implantation in patients with COPD and PH on hemodynamics, symptoms, exercise tolerance and quality of life in 10 patients in a prospective study. An improvement of objective parameters may also have a prognostic significance

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

* signed patient consent form * men and women \>30 years * Clinically indicated endoscopic lung volume reduction * Pulmonary hypertension according to Group 3.1 of the Dana Point classification * Severe pulmonary emphysema * FEV1 \<45% * RV\> 150% * TLC\> 100% * Maximum of medical therapy according to GOLD * heterogeneous emphysema * Detected in the HR-CT * Confirmation of the heterogeneity of emphysema by computer-assisted quantification (YACTA ®) * stable COPD * No exacerbation in the last 8 weeks * Cortisone dose \<20 mg prednisolone equivalent * Non-or ex-smoker * Nicotine abstinence\> 4 months * Actual CoHb \<2.5% * Diagnosis of pulmonary hypertension (PH), invasively diagnosed by right heart catheterization: * Mean pulmonary arterial pressure (mPAP)\> 25 mmHg * Pulmonary capillary wedge pressure (PCWP) \<15 mmHg * Pulmonary vascular resistance (PVR)\> 320 dyne \* sec \* cm-5

Exclusion criteria

* PH of Group 1, 2, 4, 5 of the Dana Point Classification * Previous operations * s/p Lung resection (lobectomy / pneumonectomy) * s/p endoscopic lung volume resection * significant bronchiectasis * Sputum volume\> 4 tablespoons / day * Severe cardiac comorbidities: * s/p myocardial infarction in the last 6 weeks * Congestive heart failure * Cardiomyopathy with highly impaired LVF * Clopidogrel in long-term medication * Respiratory insufficiency: PaCO2 mmHg at rest\> 55 * current pregnancy

Countries

Germany

Outcome results